Antibody-Mediated Graft Rejection Market

DelveInsight's "Antibody-Mediated Graft Rejection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Antibody-Mediated Graft Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Graft Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Antibody-Mediated Graft Rejection market report provides current treatment practices, emerging drugs, Antibody-Mediated Graft Rejection market share of the individual therapies, current and forecasted Antibody-Mediated Graft Rejection market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Antibody-Mediated Graft Rejection treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Antibody-Mediated Graft Rejection market.

Antibody-Mediated Graft Rejection Disease Understanding and Treatment Algorithm

The DelveInsight’s Antibody-Mediated Graft Rejection market report gives a thorough understanding of the Antibody-Mediated Graft Rejection by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.Antibody‐mediated rejection (AMR) is a significant complication following organ transplantation that contributes to short‐ and long‐term injury in transplant recipients. Despite desensitization protocols, up to one‐third of highly sensitized recipients may develop acute AMR following transplantation. AMR is also of significant concern in non-sensitized individuals, as de novo DSAs can develop early or late after transplantation.

The phenotype of AMR ranges from hyperacute rejection, acute AMR, and chronic AMR. AMR diagnosis depends on typical histological lesions, C4d staining, and serum DSA detection. C4d, a protein from the classical complement activation cascade that remains attached to the site of complement activation, is regarded as a diagnostic marker for AMR. The introduction of C4d as a marker of AMR aroused an ever-increasing interest in recognizing mechanisms of allograft rejection. AMR episodes occurring at different periods seem to be different clinical sub-entities. Early AMR is usually correlated with sensitization, pre-existing alloantibodies, and rapid graft dysfunction and is usually easy to be controlled; while late AMR is mostly correlated with withdrawal or reduction of immunosuppressants and noncompliance with immunosuppressive therapy, whereas late AMR has little response to antirejection strategies and thus correlate with poor graft outcomes.

The diagnosis of AMR—as defined by the modified Banff 97 and recently revised in the Banff 2019 classification—requires three cardinal features, including (a) functional evidence of allograft dysfunction, (b) morphological evidence of acute tissue injury, and evidence of Ab-dependent activation of the classical pathway of the complement system (i.e., C4d deposition in the peritubular capillaries), and detection of circulating DRSA. This report covers five major organ transplants where AMR is defined, namely Kidney, Lung, Liver, Heart, and Pancreas.

Antibody-Mediated Graft Rejection Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Antibody-Mediated Graft Rejection.

Antibody-Mediated Graft Rejection Treatment

It covers the details of conventional and current medical therapies available in the Antibody-Mediated Graft Rejection market for the treatment of the condition. It also provides Antibody-Mediated Graft Rejection treatment algorithms and guidelines in the United States, Europe, and Japan.

Antibody-Mediated Graft Rejection Epidemiology 

The Antibody-Mediated Graft Rejection epidemiology section provides insights about the historical and current Antibody-Mediated Graft Rejection patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Antibody-Mediated Graft Rejection market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Antibody-Mediated Graft Rejection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

In the year 2021, the total cases of Antibody-Mediated Graft Rejection were 5,102 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

Country Wise- Antibody-Mediated Graft Rejection Epidemiology

The epidemiology segment also provides the Antibody-Mediated Graft Rejection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Antibody-Mediated Graft Rejection Drug Chapters

The drug chapter segment of the Antibody-Mediated Graft Rejection report encloses the detailed analysis of Antibody-Mediated Graft Rejection marketed drugs and late-stage (Phase-III and Phase-II) Antibody-Mediated Graft Rejection pipeline drugs. It also helps to understand the Antibody-Mediated Graft Rejection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Antibody-Mediated Graft Rejection Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Antibody-Mediated Graft Rejection treatment.

Antibody-Mediated Graft Rejection Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Antibody-Mediated Graft Rejection treatment.

Antibody-Mediated Graft Rejection Market Outlook

The Antibody-Mediated Graft Rejection market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Antibody-Mediated Graft Rejection market trends by analyzing the impact of current Antibody-Mediated Graft Rejection therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Antibody-Mediated Graft Rejection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Antibody-Mediated Graft Rejection market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Antibody-Mediated Graft Rejection market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

This section includes a glimpse of the Antibody-Mediated Graft Rejection market in 7MM.

The United States: Antibody-Mediated Graft Rejection Market Outlook

This section provides the total Antibody-Mediated Graft Rejection market size accounted for USD 65.58 million in 2021 which is expected to rise during the study period (2019–2032).

EU-5 Countries: Antibody-Mediated Graft Rejection Market Outlook

The total Antibody-Mediated Graft Rejection market size was USD 20.50 million in 2021, which is expected to rise during the study period (2019–2032).

Japan: Antibody-Mediated Graft Rejection Market Outlook

The total Antibody-Mediated Graft Rejection market size was USD 2.24 million in 2021, which is expected to rise during the study period (2019–2032).

Antibody-Mediated Graft Rejection Drugs Uptake

This section focuses on the rate of uptake of the potential Antibody-Mediated Graft Rejection drugs recently launched in the Antibody-Mediated Graft Rejection market or expected to get launched in the market during the study period 2019-2032. The analysis covers Antibody-Mediated Graft Rejection market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Antibody-Mediated Graft Rejection Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Antibody-Mediated Graft Rejection market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Antibody-Mediated Graft Rejection Pipeline Development Activities

The Antibody-Mediated Graft Rejection market report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Antibody-Mediated Graft Rejection key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Antibody-Mediated Graft Rejection market report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Antibody-Mediated Graft Rejection emerging therapies.

Reimbursement Scenario in Antibody-Mediated Graft Rejection

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Antibody-Mediated Graft Rejection market trends, we take KOLs and SMEs ' opinion working in the Antibody-Mediated Graft Rejection domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Antibody-Mediated Graft Rejection market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Antibody-Mediated Graft Rejection Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Antibody-Mediated Graft Rejection Market Report

• The report covers the descriptive overview of Antibody-Mediated Graft Rejection, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Antibody-Mediated Graft Rejection epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Antibody-Mediated Graft Rejection is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Antibody-Mediated Graft Rejection market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Antibody-Mediated Graft Rejection market

Antibody-Mediated Graft Rejection Market Report Highlights

• In the coming years, the Antibody-Mediated Graft Rejection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Antibody-Mediated Graft Rejection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Antibody-Mediated Graft Rejection. The launch of emerging therapies will significantly impact the Antibody-Mediated Graft Rejection market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Antibody-Mediated Graft Rejection
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Antibody-Mediated Graft Rejection Market Report Insights

• Antibody-Mediated Graft Rejection Patient Population
• Antibody-Mediated Graft Rejection Therapeutic Approaches
• Antibody-Mediated Graft Rejection Pipeline Analysis
• Antibody-Mediated Graft Rejection Market Size and Trends
• Antibody-Mediated Graft Rejection Market Opportunities
• Impact of upcoming Antibody-Mediated Graft Rejection Therapies

Antibody-Mediated Graft Rejection Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Antibody-Mediated Graft Rejection Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Antibody-Mediated Graft Rejection Market
• Antibody-Mediated Graft Rejection Drugs Uptake

Antibody-Mediated Graft Rejection Market Report Assessment

• Current Antibody-Mediated Graft Rejection Treatment Practices
• Antibody-Mediated Graft Rejection Unmet Needs
• Antibody-Mediated Graft Rejection Pipeline Product Profiles
• Antibody-Mediated Graft Rejection Market Attractiveness
• Antibody-Mediated Graft Rejection Market Drivers
• Antibody-Mediated Graft Rejection Market Barriers

Key Questions

Antibody-Mediated Graft Rejection Market Insights:

• What was the Antibody-Mediated Graft Rejection drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Antibody-Mediated Graft Rejection total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Antibody-Mediated Graft Rejection market size during the forecast period (2019-2032)?
• At what CAGR, the Antibody-Mediated Graft Rejection market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Antibody-Mediated Graft Rejection market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Antibody-Mediated Graft Rejection market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Antibody-Mediated Graft Rejection Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Antibody-Mediated Graft Rejection?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Antibody-Mediated Graft Rejection patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Antibody-Mediated Graft Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Antibody-Mediated Graft Rejection?
• Out of all 7MM countries, which country would have the highest prevalent population of Antibody-Mediated Graft Rejection during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Antibody-Mediated Graft Rejection treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Antibody-Mediated Graft Rejection in the USA, Europe, and Japan?
• What are the Antibody-Mediated Graft Rejection marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Antibody-Mediated Graft Rejection?
• How many therapies are in-development by each company for Antibody-Mediated Graft Rejection treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Antibody-Mediated Graft Rejection treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Antibody-Mediated Graft Rejection therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Antibody-Mediated Graft Rejection and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Antibody-Mediated Graft Rejection?
• What are the global historical and forecasted market of Antibody-Mediated Graft Rejection?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Antibody-Mediated Graft Rejection market
• To understand the future market competition in the Antibody-Mediated Graft Rejection market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Antibody-Mediated Graft Rejection in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Antibody-Mediated Graft Rejection market
• To understand the future market competition in the Antibody-Mediated Graft Rejection market